Most total body potassium (K) is located in the intracellular space, while extracellular potassium is tightly regulated by intra-and extracellular shifts and renal excretion. 1,2 Changes in intra-and extracellular K levels modify the electrophysiological properties of the resting membrane potential in cardiac cells and subsequently influence the generation and conduction of impulses throughout the heart. 1,2 During the 1950s, hypokalemia was reported to be lower than the fibrillation threshold in isolated rabbit hearts. 3 Subsequently, relatively small observational studies reported an association between hypokalemia and the risk of ventricular arrhythmias in patients with acute myocardial infarction (AMI). 4-6 Thereafter, practice guidelines, including the American College of Cardiology/American Heart Association guidelines for management of ST-segment elevation MI (STEMI), recommended (Class I) maintaining K levels > 4.0 mEq/L although with the lowest level of evidence (C). 7,8 Moreover, even higher target levels >4.5 mEq/L were suggested, 2 yet no upper level was set. Concordantly, many hospitals implemented these guidelines by initiating treatment when serum K levels decrease below certain ''goal'' values. 1 To our knowledge, these recommendations have not been revised, since in formal guidelines and in the most recent guidelines, this issue is not mentioned directly and only the undetermined role or possible deleterious effects of glucoseinsulin-potassium (GIK) infusions are discussed. 9, 10 Ma et al, 11 in this issue of Angiology, retrospectively evaluated short-term outcomes of 6613 patients presenting with STEMI, without renal insufficiency, according to K levels at presentation. Following adjustments to potential confounders, the authors found a J-shaped relationship between patient outcomes and K levels, with lowest predefined event rate with K levels of 4 to 4.5 mEq/L. Compared to the latter reference group, multivariate analysis revealed significantly higher 30-day mortality risk in patients with K level of 4.5 to 5.0 (hazard ratio [HR]: 1.52, 95% confidence interval [CI]: 1.17-1.98; P ¼ .002) and even higher risk in patients with K level of 5.0 mEq/L (HR: 1.80, 95% CI: 1.22-2.66; P ¼ .002). This study has some limitations, particularly the relatively low adherence with contemporary guidelines, that is, insufficient use of primary percutaneous coronary intervention (PCI; only *10% of cases) and optimal medical therapy, which might compromise applicability. Nevertheless, the findings are consistent with several recent reports showing that serum K levels, outside a relatively narrow range, are associated with worse outcomes in patients presenting with AMI. [12] [13] [14] [15] [16] [17] The methodology and main findings of the latter studies are summarized in Table 1 . These studies, altogether included over 50 000 patients, consistently demonstrated that K levels are significantly associated with short-(eg, in hospital) and long-term (up to 10 years) outcomes (eg, mortality and malignant arrhythmias) in patients presenting with AMI. A study that evaluated unstable angina patients and another study evaluating the outcome of target lesion revascularization observed consistent findings. 16,17 K levels between 3.5 and 4 mEq/L (more frequently) or 4 and 4.5 mEq/L were found to be associated with lowest levels of mortality or other negative outcomes in most studies, while lower levels and even more prominently higher levels (including within normal K range) were significantly associated with worse outcomes. Furthermore, the latter association was similar regardless of K supplementation during hospitalization and seemed to be stepwise in most studies (eg, ''dose response'') further strengthening its robustness. Hence, best outcomes were reported in patients with K range for which the above-mentioned guidelines might suggest treatment to increase K levels.
Most total body potassium (K) is located in the intracellular space, while extracellular potassium is tightly regulated by intra-and extracellular shifts and renal excretion. 1, 2 Changes in intra-and extracellular K levels modify the electrophysiological properties of the resting membrane potential in cardiac cells and subsequently influence the generation and conduction of impulses throughout the heart. 1, 2 During the 1950s, hypokalemia was reported to be lower than the fibrillation threshold in isolated rabbit hearts. 3 Subsequently, relatively small observational studies reported an association between hypokalemia and the risk of ventricular arrhythmias in patients with acute myocardial infarction (AMI). [4] [5] [6] Thereafter, practice guidelines, including the American College of Cardiology/American Heart Association guidelines for management of ST-segment elevation MI (STEMI), recommended (Class I) maintaining K levels > 4.0 mEq/L although with the lowest level of evidence (C). 7, 8 Moreover, even higher target levels >4.5 mEq/L were suggested, 2 yet no upper level was set. Concordantly, many hospitals implemented these guidelines by initiating treatment when serum K levels decrease below certain ''goal'' values. 1 To our knowledge, these recommendations have not been revised, since in formal guidelines and in the most recent guidelines, this issue is not mentioned directly and only the undetermined role or possible deleterious effects of glucoseinsulin-potassium (GIK) infusions are discussed. 9, 10 Ma et al, 11 in this issue of Angiology, retrospectively evaluated short-term outcomes of 6613 patients presenting with STEMI, without renal insufficiency, according to K levels at presentation. Following adjustments to potential confounders, the authors found a J-shaped relationship between patient outcomes and K levels, with lowest predefined event rate with K levels of 4 to 4.5 mEq/L. Compared to the latter reference group, multivariate analysis revealed significantly higher 30-day mortality risk in patients with K level of 4.5 to 5.0 (hazard ratio [HR]: 1.52, 95% confidence interval [CI]: 1.17-1.98; P ¼ .002) and even higher risk in patients with K level of 5.0 mEq/L (HR: 1.80, 95% CI: 1.22-2.66; P ¼ .002). This study has some limitations, particularly the relatively low adherence with contemporary guidelines, that is, insufficient use of primary percutaneous coronary intervention (PCI; only *10% of cases) and optimal medical therapy, which might compromise applicability. Nevertheless, the findings are consistent with several recent reports showing that serum K levels, outside a relatively narrow range, are associated with worse outcomes in patients presenting with AMI. [12] [13] [14] [15] [16] [17] The methodology and main findings of the latter studies are summarized in Table 1 . These studies, altogether included over 50 000 patients, consistently demonstrated that K levels are significantly associated with short-(eg, in hospital) and long-term (up to 10 years) outcomes (eg, mortality and malignant arrhythmias) in patients presenting with AMI. A study that evaluated unstable angina patients and another study evaluating the outcome of target lesion revascularization observed consistent findings. 16, 17 K levels between 3.5 and 4 mEq/L (more frequently) or 4 and 4.5 mEq/L were found to be associated with lowest levels of mortality or other negative outcomes in most studies, while lower levels and even more prominently higher levels (including within normal K range) were significantly associated with worse outcomes. Furthermore, the latter association was similar regardless of K supplementation during hospitalization and seemed to be stepwise in most studies (eg, ''dose response'') further strengthening its robustness. Hence, best outcomes were reported in patients with K range for which the above-mentioned guidelines might suggest treatment to increase K levels.
The exact pathophysiological mechanisms by which decreased or increased K levels are associated with deleterious prognosis in patients with AMI are uncertain. The AMI was reported to be associated with several systemic metabolic changes. [18] [19] [20] These changes include increased plasma concentrations of catecholamines, free fatty acids, glucose, glycerol, cortisol, and cyclic AMP. Sekiyama et al 21 showed a transient decrease in serum K level during the acute phase of acute coronary syndrome (ACS), followed by an increase at the stable phase (discharge). The degree of the K dip was correlated with glucose level and severity of acute ischemic stress. Similarly, Wali et al 18 reported lower levels of K in patients admitted with AMI compared to controls. Such a decrease in K was related to catecholamine stimulation of the Na-K-ATPase pump, resulting in K shift intracellularly, thus causing redistributional hypokalemia. Interestingly, such an early hypokalemic dip was not seen in patients with ACS treated by beta-blockers, which are an integral part of the current guideline treatment of AMI. 22 Furthermore, hypokalemia was reported to be associated with increased risk of malignant ventricular arrhythmias in patients with AMI. [4] [5] [6] Decreased serum K levels may affect myocardial resting membrane potential, repolarization, and relative refractory time and conduction velocity. 23 Additionally, acute and chronic hypokalemia were shown to impair cardiac responses to hypoxia, and possibly impairment of calcium metabolism is involved. 24 Moreover, modest K depletion within the clinical range was found to impair contractile and relaxation responses to epinephrine. 23 However, since the report of these studies and following improvement in the management of AMI, the risk of ventricular fibrillation (VF) in this setting decreased more than 2-fold, 25 significantly minimizing the impact of such a potential complication of hypokalemia. Increased K levels, on the other hand, were associated with larger scintigraphic infarct size in patients with STEMI. 26 Concordantly, Uluganyan et al 14 recently showed that as K levels increased, the KILLIP class also increased, and at the highest K levels ejection fraction was the lowest, in patients with STEMI undergoing PCI. This finding was supported by Choi et al. 15 Considering the abovementioned, it is possible that significant K shifts rather than absolute values are associated with worse prognosis. Furthermore, it is not utterly clear whether K is a marker of severity or could itself be a potential cause of worse prognosis or possibly a combination of both.
Glucose-insulin-potassium has long been advocated and applied as an adjunctive metabolic support for the ischemic myocardium in patients with ACS. 27, 28 Although early trials of GIK infusion in the setting of AMI suggested a potential benefit, a 2010 meta-analysis of 8 randomized trials that involved >22 000 patients did not reveal any mortality benefit with GIK therapy in STEMI. 29 However, nearly all (except Glucose-Insulin-Potassium 1 [GIPS-1] study) studies examined patients with AMI 3 hours or longer after the onset of symptoms. Therefore, in the recently completed Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care Trial (IMMEDIATE) trial, 871 patients with a suspected ACS were randomized to GIK infusion or placebo in the ambulance, thereby significantly shortening system delay. 30 Early GIK infusion was associated with signals of improved outcome, including a decrease in the composite of in-hospital cardiac arrest or mortality. Complete information for serum K levels in the participating cohorts was not provided in the initial publication. The recent analysis of 1-year outcomes for the IMMEDIATE trial 31 failed to show benefit in most individual outcomes; however, the composite of cardiac arrest and 1-year mortality was lower in all those with suspected ACS, 12.8% for GIK versus 17.0% for placebo (HR 0.71, 95% CI 0.50-1.02, P ¼ .06) and in those presenting with ST-segment elevation, 10.8% with GIK versus 19.3% with placebo (HR 0.52, 95% CI 0.30-0.92, P ¼ .03). This also was the case for the 3-way composite of cardiac arrest, 1-year mortality, or heart failure hospitalization within 1 year for those presenting with STEMI (HR 0.51, 95% CI 0.30-0.87, P ¼ .01). Nevertheless, in a recent meta-analysis that included 9 RCTs (including the IMMEDIATE trial), 32 In conclusion, increasing number of contemporary observational reports consistently support a strong relationship between K levels and outcomes following AMI; both reduced K levels, and possibly more prominently increased K levels are associated with increased mortality and other negative outcomes for short-and long-term follow-up periods. Obviously, causality cannot be clearly determined from such observational studies, However, considering the high consistency of finding in various areas in the world, ACS types, post-AMI follow-up period, and other therapeutic or methodological differences and the low probability for an interventional randomized controlled study to be conducted, we suggest the following recommendations for clinical practice: close monitoring of K levels in patients with AMI, especially in patients with borderline or abnormal values upon presentation or renal failure. Careful K repletion at levels of 3.5 mEq/L or less, especially with highrisk arrhythmia features. However, aggressive K repletion or repletion at levels >3.5 mEq/L does not seem to be currently justified. Similarly, GIK infusion should not be routinely administered.
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